Other combinations of B-Raf and MEK inhibitors (e.g., vemurafenib and cobimetinib, encorafenib and binimetinib, and dabrafenib and trametinib) are used to treat melanomas with B-Raf mutations and the constitutively active MAPK/ERK pathway [22]. The gene discussed is BRAF; the disease is melanoma.